Dr. Arshad M. Khanani convened clinical operations leaders from REGENXBIO, 4D Molecular Therapeutics, Character Biosciences, and Perfuse Therapeutics for an honest conversation about how eye-care trials really get run.

Monitoring visits that repeat work already done. Endpoints verified weeks after the patient has left the chair. An appetite for AI that didn't exist twelve months ago, and almost none of it in production.

The summary covers all three, with the group's recommendations for sponsors and for CROs.

You can download the report by clicking on the link below, no email required.